HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mack, U. Search for Related Content PubMed PubMed Citation Articles by Mack, U.

LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement

For affiliations, see the Acknowledgements section.

CORRESPONDENCE: C. Lange, Division of Clinical Infectious Diseases Medical Clinic, Research Center Borstel, Parkallee 35, 23845 Borstel, Germany. Fax: 49 4537188313. E-mail: clange{at}fz-borstel.de

Keywords: Consensus statement, interferon- release assay, latent tuberculosis infection, preventive chemotherapy, tuberculin skin test, tuberculosis

Received: August 6, 2008
Accepted December 12, 2008

Tuberculosis control relies on the identification and preventive treatment of individuals who are latently infected with Mycobacterium tuberculosis. However, direct identification of latent tuberculosis infection is not possible. The diagnostic tests used to identify individuals latently infected with M. tuberculosis, the in vivo tuberculin skin test and the ex vivo interferon- release assays (IGRAs), are designed to identify an adaptive immune response against, but not necessarily a latent infection with, M. tuberculosis. The proportion of individuals who truly remain infected with M. tuberculosis after tuberculin skin test or IGRA conversion is unknown. It is also uncertain how long adaptive immune responses towards mycobacterial antigens persist in the absence of live mycobacteria. Clinical management and public healthcare policies for preventive chemotherapy against tuberculosis could be improved, if we were to gain a better understanding on M. tuberculosis latency and reactivation. This statement by the TBNET summarises knowledge and limitations of the currently available tests used in adults and children for the diagnosis of latent tuberculosis infection.

In summary, the main issue regarding testing is to restrict it to those who are known to be at higher risk of developing tuberculosis and who are willing to accept preventive chemotherapy.

This article has been cited by other articles:

				T. Zhang, M. Zhang, I. M. Rosenthal, J. H. Grosset, and E. L. Nuermberger Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection Am. J. Respir. Crit. Care Med., December 1, 2009; 180(11): 1151 - 1157. [Abstract] [Full Text] [PDF]

				L. V. Rodrigues, J. Gandara, J. Pires, R. Duarte, F. Calvario, M. Dominguez, A. Carvalho, and R. Seca Post liver transplant tuberculosis BMJ Case Reports, August 17, 2009; 2009(aug17_1): bcr0520091847 - bcr0520091847. [Abstract] [Full Text]

				C. Lange, M. Pai, F. Drobniewski, and G. B. Migliori Interferon-{gamma} release assays for the diagnosis of active tuberculosis: sensible or silly? Eur. Respir. J., June 1, 2009; 33(6): 1250 - 1253. [Full Text] [PDF]